関連する実験動画

Updated: Feb 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

5‐アザインドールコアに基づくNRAS G12D阻害剤の構造主導開発

Joshua B Cox¹, Vinay Nair¹, Pijus Mandal¹

¹Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States.

ACS medicinal chemistry letters

|February 18, 2026

まとめ

研究者らは,メラノーマなどの癌に見られるNRAS G12D変異に対する標的療法であるIACS-56676を開発した. この選択性阻害剤は,NRASの生物学とがん治療の研究のための新しいツールを提供します.

科学分野:

腫瘍学腫瘍学
分子生物学は分子生物学である.
ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー

背景:

NRAS G12D変異は,メラノーマと血液学的悪性腫瘍を誘発する.
現在,NRAS G12Dの標的治療は限られており,未満たされた臨床的ニーズを表しています.

研究の目的:

新しいNRAS G12D阻害剤であるIACS-56676の構造誘導開発について説明する.
IACS-56676をNRASの生物学研究のためのツール化合物として確立する.
NRASとKRASタンパク質の選択性を達成するための洞察を得るために.

主な方法:

構造ガイドドラッグデザインの原則が採用されました.
鉛化合物の繰り返し最適化により,効能と選択性を高めます.
NRASとKRASの変異に対する阻害剤の活性を評価するための生化学分析.

主要な成果:

IACS-56676は,NRAS G12Dの選択的で強力な阻害剤として特定されました.
p-ループの安定化とLeu 95の置換を含む主要な構造変更は,活動にとって決定的でした.
この阻害剤は,野生型KRASおよび非応答体変種に対して選択性を示した.

結論:

IACS-56676は,NRAS G12D変異を標的とした重要な進歩を表しています.
この化合物は,NRAS主導の腫瘍生成のさらなる調査のための貴重なツールとして機能します.
この研究は,選択的なRAS阻害剤の開発のための枠組みを提供します.

キーワード:

G12Dミュータントである.KRAS阻害剤によるKRAS阻害剤による NRAS NRASは,NRASとは関係ありません.SBDD,SBDDとは精密医療とは構造ベースの薬物設計ターゲットを絞った治療法です.

さらに関連する動画

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

関連する概念動画

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Preparation of 1° Amines: Gabriel Synthesis

Preparation of 1° Amines: Gabriel Synthesis

Direct alkylation is not a suitable method for synthesizing amines because it produces polyalkylated products. Gabriel synthesis is the most preferred method to exclusively make primary amines. The method uses phthalimide, which contains a protected form of nitrogen that participates in alkylation only once to predominantly give primary amines.
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Preparation of 1° Amines: Azide Synthesis

Preparation of 1° Amines: Azide Synthesis

Direct alkylation of ammonia produces polyalkylated amines, along with a quaternary ammonium salt. To exclusively prepare primary amines, the azide synthesis method can be used.
Azide ions act as good nucleophiles and react with unhindered alkyl halides to form alkyl azides. Alkyl azides do not participate in further nucleophilic substitution reactions, thereby eliminating the chances of polyalkylated products. Alkyl azides are reduced by hydride-based reducing agents, like lithium aluminum...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...